Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
JAKMIP2 antisense RNA 1 (JAKMIP2-AS1) is a long non-coding RNA (lncRNA) transcribed antisense to the JAKMIP2 locus. It does not encode a protein but exerts regulatory functions, primarily by modulating gene expression through RNA-mediated mechanisms. JAKMIP2-AS1 is significantly upregulated in colorectal cancer tissues and cell lines; its high expression promotes cancer cell proliferation and is correlated with worse clinical outcomes. Knockdown of JAKMIP2-AS1 impairs colorectal cancer cell growth in vitro and in vivo, indicating its potential as a therapeutic target and a prognostic biomarker in colorectal cancer[2][5]. As an antisense RNA, its broader molecular role aligns with gene regulation, often through interactions with complementary sense mRNAs or chromatin-modifying complexes[1][4]. There are currently no specific drugs known to directly target JAKMIP2-AS1, and no notable safety concerns have been documented for interventions at this RNA to date.
Regulatory RNA mechanisms (antisense RNA modulates expression of target mRNAs at transcriptional and post-transcriptional levels)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on JAKMIP2 antisense RNA 1 (JAKMIP2-AS1).